Antengene unveils three pipeline programs at AACR 2026 as AnTenGager platform expands beyond UCB deal
Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
Read More Pharma Industry News Lilly’s acquisition of Disarm Therapeutics: A milestone in neurodegenerative disease treatment In a significant move to bolster its portfolio in the field of neurological disease treatments, Eli Lilly and… bypharmanewsdailyOctober 16, 2020
